- Clinical Trials Community
- Challenges in IBD Research
- Current Research Studies
- Research Success
Never miss an important update! Get our latest research updates delivered right to your email inbox.
Thank you for signing up.
For over five decades, the Crohn’s & Colitis Foundation has been leading the charge to find cures for Crohn’s disease and ulcerative colitis, and to improve the quality of life for patients. We’ve made incredible strides through our research initiatives, including:
Acknowledgement: This article is a summary of “Association Between IBD Disability and Reduced Work Productivity (Presenteeism): A Population-Based Study in Manitoba, Canada” recently published in Inflammatory Bowel Diseases by Leigh Ann Shafer, PhD; John R Walker, PhD; Gayle Restall, PhD; Tarun Chhibba, MD; Meloney Ivekovic Harminder Singh, MD, MPH; Laura E Targownik, MD, MSHS; Charles N Bernstein, MD. The article was written by Nataly Shtraizent, PhD, Research Manager at the Crohn’s & Colitis Foundation.
Acknowledgement: This article is a summary of “Influences and Impact of Anxiety and Depression in the Setting of Inflammatory Bowel Disease” recently published in Inflammatory Bowel Diseases by Seyedehsan Navabi, MD, Venkata Subhash Gorrepati, MD, MPH, Sanjay Yadav, MD, Jaykrishna Chintanaboina, MD, Sarah Maher, MD, Peter Demuth, Benjamin Stern, MD, August Stuart, Andrew Tinsley, MD, Kofi Clarke, MD, Emmanuelle D Williams, MD, and Matthew D Coates, MD, PHD. This summary article was written by Catherine Soto, Director, Patient Education & Support at the Crohn’s & Colitis Foundation.
Last month, Andres Hurtado-Lorenzo, Ph.D. Senior Director of Translational Research for the Crohn’s & Colitis Foundation, had an opportunity to present “Towards Precision Medicine in Inflammatory Bowel Diseases” at the 5th Precision Medicine and Biomarkers Leaders Summit in Munich.
The Crohn's & Colitis Foundation and RTI International are working together to conduct a survey of adult patients and caregivers of pediatric patients with inflammatory bowel disease. The goal of this survey is to understand why some patients choose to participate in clinical trials and others do not. Understanding this will help researchers find ways to boost clinical trial enrollment and incorporate patient preferences in clinical trial design. The survey will take 20 minutes to complete and participants will receive a $5 gift card.
Acknowledgement: This article is a summary of “Dietary Interventions to Modulate the Gut Microbiome— how far away are we from precision medicine” recently published in Inflammatory Bowel Diseases by Francesca De Filippis, PhD, Paola Vitaglione, PhD, Rosario Cuomo, MD, Roberto Berni Canani, PhD, and Danilo Ercolini, PhD. The article was written by Nataly Shtraizent, PhD, Research Manager at the Crohn’s & Colitis Foundation.
The Sixth Annual Pediatric IBD Research Day at Weill Cornell Medicine (#PIBDRD18) will highlight scientific advances and gaps in knowledge in pediatric IBD research. The program will include presentations by nationally and internationally recognized experts, followed by question and answer periods.
Ever wonder what fecal microbiota transplantation is? Check out our latest vlog featuring Dr. Neil Nandi, Director of the Inflammatory Bowel Disease Center at Drexel University, College of Medicine.
IBD Qorus is the Crohn’s & Colitis Foundation’s quality improvement initiative designed to drive improved care and health outcomes for adult patients with IBD. Healthcare teams from centers across the United States come together to learn and share best practices for improved health care delivery. Applying these best practices in everyday care will ultimately improve the quality of care and health outcomes for IBD patients.
We know a topic of major interest within IBD community is the role that diet plays in the management of Crohn’s disease and ulcerative colitis. Unfortunately, there has been little scientific research into how diet may impact IBD but the good news is we are working to change that. In 2016, the Crohn’s & Colitis Foundation received a grant from the Patient Centered Outcomes Research Institute (PCORI) to look at two different diets and their ability to induce remission in Crohn’s patients. Foundation staff member, Rebecca Kaplan, sat down with lead investigator, Dr. Jim Lewis, during Digestive Disease Week earlier this month where they discussed the study in greater depth.
Many IBD patients – up to one third - experience significant extra-intestinal manifestations of the disease. The most common is joint inflammation. There are shared genetic and environmental factors underlying their combined pathogenesis – the process through which disease symptoms develop in the body.
On May 30th of this year, the Food and Drug Administration (FDA) approved a new treatment for moderately to severely active ulcerative colitis. Tofacitinib, which is made by Pfizer Labs, was previously approved in 2012 for rheumatoid arthritis and in 2017 for psoriatic arthritis.
Each May, Clinical Trials Day is observed to raise awareness of clinical trials and honor research professionals for their commitment and contributions to public health and medical progress. Without clinical trials, we wouldn't have medications available to treat IBD. That's why patient enrollment in clinical trials is so important. In the video below, check out our recent conversation with Brandon about his experience participating in a clinical trial, and click here to join our IBD Clinical Trials Community.
Clinical trials play a key role in the development and approval of new treatment options for IBD patients. In order to understand patient perceptions and improve recruitment, the Crohn's & Colitis Foundation conducted in-person focus groups over a four-month period in 2016, the results of which are published in the paper "Crohn’s disease and ulcerative colitis patient perspectives on clinical trials and participation."
Scientists from Dana-Farber Cancer Institute at Harvard Medical School recently reported that a specific type of bacteria that reside in the gut can enable development and dissemination of colorectal cancer.
Each of us encounters defining moments in our lives. Moments that fundamentally shape who we are, moments that reveal our true selves. I’m convinced that our deepest selves are never fully unmasked until we are faced with moments that rattle us to our core. Moments that challenge us to make a life-altering decision. Moments that test our limits. Moments lost in the unknown. Moments that inflict a pain we never imagined possible. It is precisely in these moments that I unearthed my truest self. And that self was discovered in a hospital bed.
March is Women’s History Month. The Crohn’s & Colitis Foundation would like to take this opportunity to put the spotlight on some of the fearless women leaders committed to making a difference for IBD patients. For this edition, Cecile Norris, Senior Research Manager at the Foundation, interviewed Dr. Meena Bewtra and asked her to share her story with you. Dr. Bewtra is a researcher and gastroenterologist practicing at the University of Pennsylvania, and is also an IBD patient. She has been involved with the Crohn’s & Colitis Foundation for several years, investing her time and effort in accelerating research in IBD, participating as an investigator in the Foundation’s research initiatives and advocating for patients.
In recent years, it has been increasingly recognized that the microbes which inhabit the intestinal tract, termed microbiota, have a profound impact on IBD. These microbes are essential to human health, but can become a liability during inflammatory gut disorders. Targeting these microbes via novel therapeutics may complement traditional approaches, which focus heavily on the host.
The Crohn’s & Colitis Foundation is dedicated to overcoming hurdles and accelerating innovation towards real-world improvement in IBD care. To accomplish this, every five years the Foundation updates its priorities in inflammatory bowel diseases (IBD) research, through a process entitled Challenges in IBD Research. Challenges in IBD Research recommends a global research agenda for the IBD community and guides the Foundation’s funding priorities.
We are pleased to announce that the Crohn’s & Colitis Foundation recently received a donation of $5 million from the Litwin Family. The Litwin IBD Pioneers Initiative, formerly the Broad Medical Research Program, supports researchers throughout the world by funding highly innovative pilot IBD research studies that focus on improving IBD management, including developing new diagnostic and treatment options, predicting clinically relevant disease subsets and identifying noninvasive markers of disease activity of Crohn’s disease and ulcerative colitis.
As Thanksgiving approaches, we understand that many of our patients may be thinking about the foods they may want to avoid this holiday season. Thankfully, researchers across the country have been working to better understand the role certain diets can play in the management of IBD. Last month, we blogged about Dr. Lewis’ clinical trial comparing a standard carbohydrate diet (SCD) with a Mediterranean diet. This month, we are highlighting a small study, featured in IBD News Today, which looks at the efficacy of an autoimmune protocol diet (AIP diet).
Celgene announced this week that phase 2 data of investigational compound ozanimod in Crohn's disease and ulcerative colitis will be presented at the World Congress of Gastroenterology at ACG2017 (WCOG at ACG2017) in Orlando. The studies include new data from the STEPSTONE study in patients with moderately to severely active Crohn's disease (CD) and long-term data from the open-label extension of the TOUCHSTONE study in patients with moderately to severely active ulcerative colitis (UC). Ozanimod is an investigational, selective sphingosine 1-phosphate (S1P) 1 and 5 receptor modulator.
There has been a lot of buzz throughout the IBD Community about the role diet plays in the management of IBD. This month, we are highlighting Dr. James D. Lewis’s study, which received funding to determine if the specific carbohydrate diet (SCD) is superior to the Mediterranean-style diet (MSD) for patients with active Crohn’s disease.
In order to have a positive impact in IBD, it is critical that foundations work together to fund the many different types of research needed to advance the field towards potential cures. That’s why we are excited that our colleagues at the Kenneth Rainin Foundation have launched an online resource to inspire collaboration in Inflammatory Bowel Disease research.
The independent Data and Safety Monitoring Board (DSMB) has reviewed safety and efficacy data from the first 222 patients enrolled in RedHill's Phase III Map US study who have completed 26 weeks of assessment and unanimously recommended the study continue as planned.
Earlier last month, Seres Therapeutics, Inc. announced that it has completed enrollment for its ongoing SER-287 Phase 1b clinical study of 58 patients suffering from mild-to-moderate ulcerative colitis who are failing current therapies. Enrollment in this trial is especially noteworthy as the SER-287 study is the first microbiome therapeutic candidate to reach clinical‐stage development in a chronic inflammatory disease, and the first in an indication outside of infectious disease.
The Crohn’s & Colitis Foundation’s “RISK Stratification” study is the largest new-onset study completed on pediatric Crohn’s disease patients. In early 2017, researchers successfully identified biological signatures in pediatric patients with newly diagnosed Crohn’s disease capable of predicting whether a child will develop disease-related complications requiring major surgery within three to five years.
We are glad that you stopped by and hope that you take some time to check out all of the new resources created as part of this initiative. Our Community was created to help raise awareness of IBD clinical trials happening all over the country and to educate patients, caregivers, and physicians about the value of participating in clinical research. As many of you may already know, by participating in IBD clinical trials, patients and physicians help accelerate the development of new treatment options for the IBD community. And because IBD is so specific to each individual patient, having a number of treatment options available to the patient is a key component to successfully managing the disease.
I found the information on this page:
Thank you for your feedback!
Never miss an important update! Get our latest research updates delivered right to your email inbox.
Thank you for registering!
We have successfully added you to our email list. Watch your inbox for updates from the Clinical Trials Community!